GeNeuro and Servier Announce Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017
Geneva, Switzerland, and Paris, France, October 28, 2017 – 11:00 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today post hoc analyses of 6-month data from the CHANGE-MS Phase 2b study of GNbAC1 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results showed an anti-inflammatory effect in active patients at the highest (18 mg/kg) of the three doses tested at Week 24. In addition, at the same dose, a promising effect on remyelination was observed at 24 weeks.
More information on